Unimed stock (TN0007230011): Tunisian pharma player in focus after recent stock move

Unimed, a Tunisian pharmaceutical manufacturer listed in Tunis, has drawn attention after a recent share price move on the local exchange. The company’s focus on sterile injectable drugs and export markets makes it relevant for internationally oriented and US-based investors tracking emerging-market healthcare.

Unimed, a Tunisia-based pharmaceutical producer of sterile medicines, has come into focus after a recent move in its share price on the Bourse de Tunis, where it trades under the ticker UMED. The stock changed hands at 8.00 TND on 04/18/2025 according to data from the Tunis Stock Exchange, reflecting noticeable activity in a relatively illiquid emerging-market healthcare name for globally diversified investors.

As of: 05/22/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Unimed
• Sector/industry: Pharmaceuticals, sterile injectables
• Headquarters/country: Tunisia
• Core markets: Domestic Tunisian market and export markets in selected regions
• Key revenue drivers: Contract manufacturing and branded injectable drugs
• Home exchange/listing venue: Bourse de Tunis (ticker: UMED)
• Trading currency: Tunisian dinar (TND)

Unimed: core business model

Unimed is a pharmaceutical company headquartered in Tunisia that specializes in the production of sterile medicines, particularly injectable forms such as vials, ampoules and other parenteral formats. The company focuses on therapies that require stringent manufacturing standards, including anti-infectives, anesthetics and other hospital-oriented products, according to information on its corporate website Unimed website as of 03/15/2025.

The company operates production facilities designed to comply with international quality standards for sterile pharmaceuticals, including clean-room environments and specialized filling lines. Unimed supplies products both under its own brands and as a contract manufacturer for other pharmaceutical firms, which can diversify its revenue sources between proprietary formulations and manufacturing services, according to a company presentation published in 2024 on its site Unimed website as of 10/02/2024.

Beyond Tunisia, Unimed targets export markets, with a historical focus on neighboring North African countries and selected regions in the Middle East and Sub-Saharan Africa. This export orientation gives the group exposure to broader demographic and healthcare spending trends in emerging markets while still being anchored in its domestic base, according to its corporate profile pages updated in 2024 on the company website Unimed website as of 11/21/2024.

Main revenue and product drivers for Unimed

Unimed’s revenue base is centered on injectable drugs used primarily in hospital and clinical settings. These include antibiotics, anesthetics and other sterile preparations that require cold-chain logistics and precise dosing formats. Hospital demand tends to be less discretionary than consumer health products, which can support relatively stable volumes, according to a description of Unimed’s portfolio in its 2023 corporate brochure published in 2024 on the company site Unimed website as of 09/30/2024.

A significant revenue driver is contract manufacturing, where Unimed uses its sterile production lines to manufacture products for partner companies. This business model allows the company to leverage its fixed-cost base and technical expertise without bearing all the commercial and marketing risk associated with launching new brands, according to a manufacturing services overview released by Unimed in 2024 on its website Unimed website as of 07/12/2024.

Unimed also invests in developing and registering its own branded generic medicines in various therapeutic classes, which can support higher margins compared with pure contract manufacturing. The portfolio includes injectable generics aligned with national essential medicines lists and regional demand patterns, according to a product catalog made available on the company’s website and dated 2024 Unimed website as of 06/05/2024.

Conclusion

Unimed offers exposure to the pharmaceutical sector in North Africa, with a focus on sterile injectables and hospital-oriented products manufactured in Tunisia. The company combines contract manufacturing with its own branded generics and maintains a growing export footprint in selected emerging markets. For internationally diversified and US-based investors tracking healthcare opportunities beyond developed-market large caps, the stock illustrates the characteristics and risks of investing in smaller, regionally focused pharma manufacturers in frontier markets, including currency factors, regulatory environments and market liquidity on the local Tunis exchange.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.